Bridge Biotherapeutics’ partnering strategy and growth by external innovation In this biotech networking event, two speakers from Bridge Biotherapeutics talked about the history of their…
Adrian Limani25.05.2023
Our portfolio company, Phialogics - a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases, closed a €600k pre-seed…
Adrian Limani21.04.2023
Engimmune Therapeutics, a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, has announced the appointment of Dr. Lars Nieba as Chief Executive Officer. Engimmune…
Adrian Limani21.04.2023
We are delighted to announce that our portfolio has blown past half a billion dollars raised to now collectively reach over $550M! Just the last…
Adrian Limani13.04.2023
Alentis Therapeutics is a thriving clinical-stage biotech company in Basel, Switzerland, developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The company, lead by…
Adrian Limani13.04.2023
Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…
Adrian Limani30.03.2023
What startups need to know about term sheets, legal due diligence and employee incentives Conducting legal due diligence and preparing and negotiating term sheets for…
Adrian Limani13.01.2023
Building biotech companies and raising venture capital financing In our latest event co-organized with Pureos, we had three extraordinary biotech founders (one of them who…
Adrian Limani05.01.2023
